Sulforaphane is a naturally occurring active substance found in vegetables that is known for its potential in preventing and treating cancer. This compound has demonstrated promising effects in inhibiting the growth of various types of cancer, including esophageal, lung, colon, breast, and liver cancer. However, its instability towards pH and heat limits its application in the medical and food industries. To address this challenge, novel drug delivery systems have been developed to improve the stability and efficacy of sulforaphane, making it a more suitable candidate for clinical use in cancer research. In this study, nanocomposite materials were prepared using multi-walled carbon nanotubes (MWCNTs) and chitosan (CS) as base materials, with polydopamine (PDA) acting as a bridge material. The synthesized composite materials were used as drug carriers for the release of sulforaphane. The results of the study showed that the drug loading increased with an increase in the concentration of sulforaphane, indicating that the nanocomposite materials were effective in delivering and releasing the drug. Moreover, a positive correlation was observed between the drug loading and the thickness of the PDA layer. These findings suggest that the use of MWCNTs, CS, and PDA in the development of drug delivery systems can enhance the stability and efficacy of sulforaphane, potentially leading to improved cancer treatment outcomes.

Study on the controlled release properties of modified multi-walled carbon nanotubes on sulforaphane
    Abstract
    1 Introduction
    2 Experimental
        2.1 Chemicals and instruments
        2.2 Preparation of CSPDA-MWCNT and CSPDAM-MWCNT
        2.3 Controlled release properties of CSPDA-MWCNT and CSPDAM-MWCNT toward sulforaphane
    3 Results and discussion
    4 Conclusion
    References

• Ronghua Li(Department of Anesthesiology, Cangzhou Central Hospital, Cangzhou 061000, Hebei, People’s Republic of China)
• Xiucai Hu(Department of Anesthesiology, Cangzhou Central Hospital, Cangzhou 061000, Hebei, People’s Republic of China)
• Shiqiang Shan(Department of Anesthesiology, Cangzhou Central Hospital, Cangzhou 061000, Hebei, People’s Republic of China)
• Yongbo Li(Department of CT Diagnostic Department, Cangzhou Central Hospital, Cangzhou 061000, Hebei, People’s Republic of China)
• Wenbin Cui(Department of Anesthesiology, Cangzhou Central Hospital, Cangzhou 061000, Hebei, People’s Republic of China)
• Lingling Liu(Department of Anesthesiology, Cangzhou Central Hospital, Cangzhou 061000, Hebei, People’s Republic of China)